TWI796340B - 處理腫瘤之方法中使用的包含奈米顆粒的醫藥組合物 - Google Patents

處理腫瘤之方法中使用的包含奈米顆粒的醫藥組合物 Download PDF

Info

Publication number
TWI796340B
TWI796340B TW107123130A TW107123130A TWI796340B TW I796340 B TWI796340 B TW I796340B TW 107123130 A TW107123130 A TW 107123130A TW 107123130 A TW107123130 A TW 107123130A TW I796340 B TWI796340 B TW I796340B
Authority
TW
Taiwan
Prior art keywords
tumor
nanoparticles
cells
aforementioned
pharmaceutical composition
Prior art date
Application number
TW107123130A
Other languages
English (en)
Chinese (zh)
Other versions
TW201906636A (zh
Inventor
弗朗索瓦 勒克斯
奧利維爾 蒂耶芒
讓呂克 皮爾菲提
埃里克 多伊奇
弗雷德里克 羅
阿沃特夫 艾路什
Original Assignee
法商Ｎｈ蕾哈吉公司
法國里昂第一大學
法國國家科學研究院
國家衛生及醫學研究院
古士塔柏羅斯學院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商Ｎｈ蕾哈吉公司, 法國里昂第一大學, 法國國家科學研究院, 國家衛生及醫學研究院, 古士塔柏羅斯學院 filed Critical 法商Ｎｈ蕾哈吉公司
Publication of TW201906636A publication Critical patent/TW201906636A/zh
Application granted granted Critical
Publication of TWI796340B publication Critical patent/TWI796340B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW107123130A 2017-07-05 2018-07-04 處理腫瘤之方法中使用的包含奈米顆粒的醫藥組合物 TWI796340B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305869.4A EP3424533A1 (en) 2017-07-05 2017-07-05 Methods for treating tumors
EPEP17305869 2017-07-05

Publications (2)

Publication Number Publication Date
TW201906636A TW201906636A (zh) 2019-02-16
TWI796340B true TWI796340B (zh) 2023-03-21

Family

ID=59363059

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107123130A TWI796340B (zh) 2017-07-05 2018-07-04 處理腫瘤之方法中使用的包含奈米顆粒的醫藥組合物

Country Status (9)

Country Link
US (1) US20210128730A1 (enExample)
EP (2) EP3424533A1 (enExample)
JP (1) JP7386711B2 (enExample)
KR (1) KR102799910B1 (enExample)
CN (1) CN110913909A (enExample)
AU (1) AU2018296426B2 (enExample)
CA (1) CA3068355A1 (enExample)
TW (1) TWI796340B (enExample)
WO (1) WO2019008040A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2959502B1 (fr) 2010-04-30 2012-09-07 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie
KR20220106736A (ko) 2019-07-29 2022-07-29 엔에이취 테라귁스 종양 치료 방법
FR3099883A1 (fr) 2019-08-14 2021-02-19 Nh Theraguix Nanoparticules pour le traitement du cancer par rayonnement de radiofréquence
TWI833803B (zh) * 2019-09-12 2024-03-01 法商Ｎｈ蕾哈吉公司 含有高ｚ元素之奈米顆粒在製備用於治療腫瘤之藥物之用途
EP3795178A1 (en) 2019-09-19 2021-03-24 Nh Theraguix Methods for triggering m1 macrophage polarization
WO2021154746A1 (en) 2020-01-28 2021-08-05 Reflexion Medical, Inc. Joint optimization of radionuclide and external beam radiotherapy
WO2021228867A1 (en) 2020-05-15 2021-11-18 Universite Claude Bernard Lyon 1 Methods for image-guided radiotherapy
CA3084780A1 (en) * 2020-06-24 2021-12-24 Rodney HERRING Use of low iron oxide iron-doped titanium dioxide nanoparticles in the treatment of tumors and other diseases
FR3116197A1 (fr) 2020-11-19 2022-05-20 Nh Theraguix Procédé de traitement de tumeurs par captation du cuivre et/ou du fer
FR3116216B1 (fr) 2020-11-19 2023-10-27 Nh Theraguix Procédé de préparation de nanoparticules
CN120359049A (zh) 2022-07-13 2025-07-22 蒙彼利埃大学 纳米颗粒和放射性药物的联合疗法
CN120225206A (zh) * 2022-09-16 2025-06-27 株式会社韩国原子力工学 具有远端效应的用于预防或者治疗癌症的组合物，以及使用该组合物预防或者治疗癌症的方法
EP4605019A2 (en) 2022-10-18 2025-08-27 Nh Theraguix Methods for imaging using spcct
WO2024236048A1 (en) 2023-05-16 2024-11-21 Nh Theraguix Combination therapy for treating tumors with radiotherapy
FR3151755A1 (fr) 2023-07-31 2025-02-07 Nh Theraguix Procédé de quantification de la concentration d’un agent de contraste et dispositif associé

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130195766A1 (en) * 2010-04-30 2013-08-01 Nanoh Ultrafine nanoparticles comprising a functionalized polyorganosiloxane matrix and including metal complexes; method for obtaining same and uses thereof in medical imaging and/or therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026748A2 (en) * 2000-09-25 2002-04-04 The Procter & Gamble Company Metal complexes for use in medical and therapeutic applications
FR2867180B1 (fr) 2004-03-02 2006-06-16 Univ Claude Bernard Lyon Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
GB0704932D0 (en) * 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
CN104684546A (zh) * 2012-06-07 2015-06-03 哈佛大学校长及研究员协会 用于药物靶向的纳米疗法
US9726661B2 (en) * 2012-07-06 2017-08-08 Institut Gustave-Roussy Simultaneous detection of cannibalism and senescence as prognostic marker for cancer
PL2948179T3 (pl) * 2013-01-25 2019-10-31 Nanobiotix Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu
KR101662755B1 (ko) * 2015-04-28 2016-10-05 한국생명공학연구원 Nox5의 발현 또는 활성을 억제하는 제제를 포함하는 암 치료용 조성물
JP2018516256A (ja) * 2015-05-28 2018-06-21 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 治療用ワクチンとしての使用のためのナノ粒子
WO2016196894A1 (en) * 2015-06-03 2016-12-08 Kradl Therapeutics, Llc Compositions of polyunsaturated fatty acids and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130195766A1 (en) * 2010-04-30 2013-08-01 Nanoh Ultrafine nanoparticles comprising a functionalized polyorganosiloxane matrix and including metal complexes; method for obtaining same and uses thereof in medical imaging and/or therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Mowat et al., "In Vitro Radiosensitizing Effects of Ultrasmall Gadolinium Based Particles on Tumour Cells", Journal of Nanoscience and Nanotechnology, 11, 2011, pp 1-7. *

Also Published As

Publication number Publication date
JP2020525467A (ja) 2020-08-27
TW201906636A (zh) 2019-02-16
EP3648793A1 (en) 2020-05-13
CA3068355A1 (en) 2019-01-10
EP3424533A1 (en) 2019-01-09
KR20200026290A (ko) 2020-03-10
KR102799910B1 (ko) 2025-04-25
US20210128730A1 (en) 2021-05-06
WO2019008040A1 (en) 2019-01-10
JP7386711B2 (ja) 2023-11-27
AU2018296426B2 (en) 2024-04-04
AU2018296426A1 (en) 2020-01-16
CN110913909A (zh) 2020-03-24

Similar Documents

Publication Publication Date Title
KR102799910B1 (ko) 종양 치료 방법
Chen et al. Hypoxic tumour cell-derived exosomal miR-340-5p promotes radioresistance of oesophageal squamous cell carcinoma via KLF10
Du et al. Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy
Kim et al. STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers
Miyazaki et al. CD44 exerts a functional role during EMT induction in cisplatin-resistant head and neck cancer cells
Cesi et al. Transferring intercellular signals and traits between cancer cells: Extracellular vesicles as “homing pigeons”
de Paula et al. Targeting senescence as a therapeutic opportunity for triple-negative breast cancer
CA2979792C (en) Method for diagnosing, preventing and treating cancer brain metastasis, and drug delivery system for enabling passage through blood-brain barrier
CN101313219B (zh) 一种诊断和治疗方法及其所使用的试剂
Tripathi et al. Biological Cargo: Exosomes and their Role in Cancer Progression and Metastasis
US20230218781A1 (en) Methods for triggering m1 macrophage polarization
Yang et al. Combination of porous Se@ SiO2 nanospheres and docetaxel exhibits anti-castration-resistant prostate cancer activity by downregulating ATG14-dependent autophagy
AU2010237572B2 (en) Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof
Joshi et al. Exosome and other extracellular vesicles for cancer management
CN105732811A (zh) 一种新型抗cd20抗体纳米列阵、其制备方法及用途
Lee et al. Exosomal MicroRNA-151a-3p Improves the Sensitivity to Radiotherapy via the Interaction between p53 and Histone Deacetylase 5
US20170176445A1 (en) Method for determining the level of hypoxia in a tumor
Mc Namee et al. BBA-Reviews on Cancer
Boldrini et al. Increased cytotoxic effects via combined treatment of magnetic field and radiation therapy in patient-derived organoids of pancreatic ductal adenocarcinoma
WO2024236048A1 (en) Combination therapy for treating tumors with radiotherapy
Longy Rapsodie: pour saxophone alto mi♭/G. Longy.
Rade Proteasome Inhibitors Enhance Endothelial Thrombomodulin Expression via Induction of Krüppel-Like Transcription Factors
羽村凌雅 et al. Suppression of lysosomal acid alpha-glucosidase impacts the modulation of transcription factor EB translocation in pancreatic cancer
Yang Early Detection of Breast Cancer Using Molecular Beacons
Class et al. Patent application title: METHODS FOR DETECTION, DIAGNOSIS AND SELECTIVE ERADICATION OF NEOPLASMS IN VIVO USING MULTIDOMAIN BIOTAGS Inventors: Marek Malecki (Pomona, CA, US) Raf Malecki (San Francisco, CA, US)

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees